KEEPER-SECURITY
9.7.2021 09:02:08 CEST | Business Wire | Press release
UK businesses are struggling to deal with multiple urgent cybersecurity challenges, new research by Keeper Security has revealed. The 2021 Cybersecurity Census Report shows cyberattacks are becoming more vicious, frequent and sophisticated, while UK businesses are underprepared and too slow to counter these attacks. As a result, senior leaders within UK organisations are preoccupied with playing a cyberattack blame game instead of investing in boosting their defences.
The report has found that more than nine in ten (92%) UK business suffered a cyberattack in the last 12 months and three quarters (78%) feel unprepared to deal with this threat. Nearly a third (31%) believe CTOs should take the blame in the case of a successful cyberattack. Such a weight of responsibility means cybersecurity standards are dropping: 36% of senior IT leaders confess to having kept a cyberattack to themselves, while 32% admit to using weak credentials such as ‘password’ or ‘admin’ to protect their data.
“UK businesses are clearly worried about their cybersecurity and, as our report has found, the challenges are manifold, affecting everything from budgets to productivity,” said Darren Guccione, CEO & co-founder, Keeper Security. “While there is a desire to boost security efforts, companies are facing many competing challenges right now and, understandably, might not always make cybersecurity investments a priority. Our report is an urgent reminder for organisations to proactively address their cybersecurity challenges as a priority since deferring them will make the consequences far more severe.”
Key findings include:
- Almost all (92%) UK organisations are aware of gaps or weak links in their cybersecurity defences are, but less than half (40%) are actively addressing all of them
- Two-thirds (66%) of UK organisations have relaxed their cybersecurity policies over the past 12 months so staff can work remotely or in order not to stifle productivity
- 58% of IT professionals feel employees at their organisations do not understand the full consequences of poor cyber-hygiene
- 61% of UK companies have a skills shortage in cybersecurity
- The financial fallout of cyberattacks has been damaging, too, costing nearly one in ten (8%) UK businesses over £1 million
- An overwhelming 87% of IT leaders support the creation of a nationwide governing body to hold businesses to account when it comes to best online security practices
- And almost all (91%) are in agreement that UK businesses should be legally required to have basic cybersecurity protections in place to be allowed to operate
“Companies are struggling to put the right solutions in place to cope with cyberattacks and the consequences are both damaging and costly,” said Craig Lurey, CTO and co-founder, Keeper Security. “The conditions caused by Covid-19 have led to an increased amount of hybrid working, making effective cybersecurity defences even harder to achieve. But if businesses want to bounce back fully after the pandemic, they must get their security hygiene in order without delay.”
Despite the rise in cyberattacks and increasing pressures felt by security teams, more than a quarter of UK companies (28%) do not consider IT to be even in their top three priorities as they plan for the next 12 months. This is particularly worrying, given almost all (92%) UK organisations know where the gaps or weak links in their cybersecurity defences are but well under half (40%) are actively addressing them.
Guccione concludes: “While this situation can't be rectified overnight, there are straightforward steps UK businesses can take to boost their cyber defences. First, organisations should do a comprehensive cybersecurity audit, looking at where the gaps lie and how they can be addressed. Next, they need to put in place a clear plan of action for how to address these challenges. Running cybersecurity training sessions to educate employees and introducing a password management platform to keep credentials safe and secure are two simple, yet highly effective actions business can take today, to be better prepared against cyberattacks tomorrow.”
+++ ENDS +++
About Keeper Security Inc.
Keeper Security, Inc. (Keeper) is the highly-rated and patented cybersecurity platform for preventing password-related data breaches and cyberthreats. Keeper’s zero-knowledge security and encryption software is trusted by millions of people and thousands of businesses across the globe to mitigate the risk of cybertheft, boost employee productivity and meet compliance standards. Keeper has been named PC Magazine’s Best Password Manager of the Year & Editors’ Choice, PCWorld’s Editors’ Choice and is the winner of four G2 Best Software Awards and the InfoSec Award for Best Product in Password Management for SMB Cybersecurity. Keeper is SOC-2 and ISO 27001 Certified and is also listed for use by the U.S. federal government through the System for Award Management (SAM). Learn more at https://keepersecurity.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210709005049/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
